Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - granules - montelukast as sodium 4 mg - montelukast - singulair is indicated in adult and pediatric patients 12 months of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin - sensitive asthmatic patients, and the prevention of exercise - induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma.singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - chewable tablets - montelukast as sodium 5 mg - montelukast - montelukast - singulair 5 mg is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms of the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with seasonal rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an intolerance to alternative therapies.

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - tablets - montelukast as sodium 10 mg - montelukast - montelukast - singulair 10 mg is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms of the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with seasonal rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an intolerance to alternative therapies.

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - chewable tablets - montelukast as sodium 4 mg - montelukast - montelukast - singulair is indicated in pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with seasonal rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an intolerance to alternative therapies.

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - tablets controlled release - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - tablets - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar 50 mg is indicated for the treatment of hypertensionheart failure: ocsaar 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to ocsaar 50 mg is not recommended.renal protection in type-2 diabetic patients with proteinuria: ocsaar 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.the benefit of ocsaar 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - tibolone - tablets - tibolone 2.5 mg - tibolone - tibolone - • complaints resulting from the natural or artificial menopause.treatment of oestrogen deficiency symptoms in postmenopausal women, more than one year after menopause. women above 60 years of age should only start with livial treatment when they are intolerant of, or contraindicated for, other medicinal products approved for the treatment of oestrogen deficiency symptoms.• prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.for all women the decision to prescribe tibolone livial should be based on an assessment of the individual patient’s overall risks and, particularly in the over 60s, should include consideration of the risk of stroke.

Իսրայել - անգլերեն - Ministry of Health

merck sharp & dohme israel ltd - desogestrel; ethinylestradiol - tablets - desogestrel 150 mcg; ethinylestradiol 20 mcg - desogestrel - desogestrel - oral contraception

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - finasteride - film coated tablets - finasteride 1 mg - finasteride - finasteride - propecia is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - tablets controlled release - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.